University of Oulu

Secreters - A new generation of microbial expression hosts and tools for the production of biotherapeutics and high-value enzymes (813979)

Saved in:
Description:
The ‘SECRETERS’ partnership aims to bring about a step change in the production of recombinant proteins, particularly Biotherapeutics and Industrial Enzymes. Both are critical products for the EU biotechnology sector, with combined markets in excess of $140 billion p.a.; the former are essential for the treatment of major diseases whereas the latter permeate every aspect of our daily life. Many proteins in these categories pose severe problems in production, especially disulphide-bonded proteins and new format 'difficult-to-express' proteins. SECRETERS will train a team of 15 ESRs to develop a new generation of super-producing microbial production hosts, including Escherichia coli, Bacillus species and the yeast Pichia pastoris. The project capitalises on a series of recent innovations and involves close collaboration between 5 academic Beneficiaries, who provide world-leading expertise in redox chemistry, synthetic biology and protein expression, and 5 non-academic Beneficiaries, who include some of the world's premier biotherapeutic and industrial enzyme companies. It will enable the biotherapeutics industry to produce challenging medicines at lower costs, resulting in new drugs and wider patient access, and allow the enzymes industry to deliver a range of powerful new products. SECRETERS will equip ESRs with the interdisciplinary and intersectoral skills required to thrive in these industries, with quality assurance systems embedded throughout the programme and a commitment to a wide-ranging dissemination/outreach programme. Based on a responsible innovation approach, with clear foci on research and entrepreneurial training, SECRETERS will deliver a team of superbly-trained scientists, poised to engage in some of Europe's most important biotechnology sectors.
see all

Subjects:
Grant Number: 813979
Cordis Record Number: 218528
Project Start Date: 2019-01-01
Project End Date: 2022-12-31
Project Funder: EC/H2020/MSCA-ITN-ETN/
EC Special Clause: false
Datapilot: true
Open Access Mandate: true
Coordinator: ACADEMISCH ZIEKENHUIS GRONINGEN
Coordinator EU Contribution: 531239.76
EU Max Contribution: 4087420.92
Total Cost: 4087420.92
Participant: OULUN YLIOPISTO
UCB PHARMA SA
UNIVERSITATSMEDIZIN GREIFSWALD KORPERSCHAFT DES OFFENTLICHEN RECHTS
ACIB GMBH
CELLTECH R&D LIMITED
LONZA AG
AB Enzymes GmbH
UNIVERSITY OF KENT
HUMBOLDT-UNIVERSITAET ZU BERLIN
BOEHRINGER INGELHEIM RCV GMBH & CO KG
UNIVERSITAET GREIFSWALD
More information: Detailed project information (CORDIS)
Detailed project information (Openaire)
Copyright information: © European Union, 1994-2017 CORDIS, http://cordis.europa.eu/
All materials created by the OpenAIRE consortium are licensed under a Creative Commons Attribution 4.0 International License
  http://cordis.europa.eu/
https://creativecommons.org/licenses/by/4.0/